



## Review article

## Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry

Philippe De Deurwaerdère<sup>a,\*</sup>, Giuseppe Di Giovanni<sup>b,c</sup>, Mark J. Millan<sup>d</sup><sup>a</sup> CNRS (Centre National de la Recherche Scientifique), Institut des Maladies Neurodégénératives, UMR CNRS 5293, F-33000 Bordeaux, France<sup>b</sup> Neuroscience Division, School of Biosciences, Cardiff University, Cardiff, UK<sup>c</sup> Department of Physiology & Biochemistry, Faculty of Medicine and Surgery, University of Malta, Malta<sup>d</sup> Institut de Recherche Servier, Pole for Therapeutic Innovation in Neuropsychiatry, 78290 Croissy/Seine, Paris, France

## ARTICLE INFO

## Article history:

Received 20 April 2016

Received in revised form 18 June 2016

Accepted 3 July 2016

Available online 4 July 2016

## Keywords:

Parkinson's disease

Serotonin

Dopamine

Basal ganglia

Dyskinesia

Striatum

## ABSTRACT

Though a multi-faceted disorder, Parkinson's disease is prototypically characterized by neurodegeneration of nigrostriatal dopaminergic neurons of the substantia nigra pars compacta, leading to a severe disruption of motor function. Accordingly, L-DOPA, the metabolic precursor of dopamine (DA), is well-established as a treatment for the motor deficits of Parkinson's disease despite long-term complications such as dyskinesia and psychiatric side-effects. Paradoxically, however, despite the traditional assumption that L-DOPA is transformed in residual striatal dopaminergic neurons into DA, the mechanism of action of L-DOPA is neither simple nor entirely clear. Herein, focussing on its influence upon extracellular DA and other neuromodulators in intact animals and experimental models of Parkinson's disease, we highlight effects *other* than striatal generation of DA in the functional profile of L-DOPA. While not excluding a minor role for glial cells, L-DOPA is principally transformed into DA in neurons yet, interestingly, with a more important role for *serotonergic* than dopaminergic projections. Moreover, in addition to the striatum, L-DOPA evokes marked increases in extracellular DA in frontal cortex, nucleus accumbens, the subthalamic nucleus and additional extra-striatal regions. In considering its functional profile, it is also important to bear in mind the marked (probably indirect) influence of L-DOPA upon cholinergic, GABAergic and glutamatergic neurons in the basal ganglia and/or cortex, while anomalous serotonergic transmission is incriminated in the emergence of L-DOPA elicited dyskinesia and psychosis. Finally, L-DOPA may exert intrinsic receptor-mediated actions independently of DA neurotransmission and can be processed into bioactive metabolites. In conclusion, L-DOPA exerts a surprisingly complex pattern of neurochemical effects of much greater scope than mere striatal transformation into DA in spared dopaminergic neurons. Their further experimental and clinical clarification should help improve both L-DOPA-based and novel strategies for controlling the motor and other symptoms of Parkinson's disease.

© 2016 Elsevier Ltd. All rights reserved.

**Abbreviations:** AADC, aromatic L amino acid decarboxylase; COMT, catechol-O-methyl-transferase; CSF, cerebrospinal fluid; 6-OHDA, 6-hydroxydopamine; DBH, dopamine β-hydroxylase; DOPAC, 3,4-dihydroxyphenylacetic acid; 3-MT, 3-methoxytyramine; DA, dopamine; DAT, dopamine transporter; DRN, dorsal raphe nucleus; DSP-4, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine; MRN, median raphe nucleus; GP, globus pallidus; GPe, globus pallidus pars externa; GPi, globus pallidus pars interna; EPN, entopeduncular nucleus; HVA, homovanillic acid; HDC, histidine decarboxylase; HFS-STN, high frequency stimulation of the subthalamic nucleus; L-DOPA, levodopa 3,4-dihydroxy-L-phenylalanine; MAOA, monoamine oxidase A; MAOB, monoamine oxidase B; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson's disease; PET, positron emission tomography; 5-HIAA, 5-hydroxyindolacetic acid; 5-HT, serotonin or 5-hydroxytryptamine; 5-HTP, 5-hydroxytryptophan; NA, noradrenaline; SERT, serotonin transporter; NET, noradrenaline transporter; OCT, organic cation transporter; SN, substantia nigra; SNpc, substantia nigra pars compacta; SNpr, substantia nigra pars reticulata; STN, subthalamic nucleus; SSRI, selective serotonin reuptake inhibitor; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; TTX, tetrodotoxin; VMAT2, vesicular monoamine transporter 2.

\* Corresponding author.

E-mail address: [deurwaer@u-bordeaux.fr](mailto:deurwaer@u-bordeaux.fr) (P. De Deurwaerdère).

## Contents

1.	Introduction: Parkinson's disease and its management by L-DOPA, an overview and aims of the review	58
2.	Deciphering the functional properties and mechanism of action of L-DOPA	59
2.1.	L-DOPA as an antiparkinson agent: historical perspective on beneficial and undesirable actions	59
2.2.	Animal models of Parkinson's disease for the study of L-DOPA	60
2.3.	Comparative doses of L-DOPA between humans and animal models	60
3.	L-DOPA and its transformation into DA in normal and Parkinson tissue	62
3.1.	L-DOPA uptake leading to DA synthesis and release	62
3.2.	Cellular origin of DA and metabolic pathways following administration of L-DOPA: studies on cerebral tissue	63
3.3.	Neuronal origin of L-DOPA-induced DA release	64
4.	Role of specific classes of monoaminergic neuron in L-DOPA-driven DA synthesis and release	64
4.1.	Evidence for the involvement of monoaminergic neurons in L-DOPA-induced DA synthesis and release	64
4.2.	Role of spared dopaminergic pathways in L-DOPA-mediated DA synthesis and release	64
4.3.	Role of adrenergic pathways in L-DOPA-mediated DA synthesis and release	67
4.4.	Role of serotonergic pathways in L-DOPA-mediated DA synthesis and release	67
4.5.	Role of histaminergic pathways in L-DOPA-mediated DA synthesis and release	68
4.6.	Summary of neuronal substrates of L-DOPA-mediated DA synthesis and release	69
5.	The complex and variable influence of L-DOPA upon extracellular DA	69
5.1.	L-DOPA-derived DA release in intact and lesioned rats in relation to motor function	69
5.2.	Role of clearance in the influence of L-DOPA upon extracellular levels of DA	70
5.3.	Impulse-dependent and independent (non-exocytotic) L-DOPA-derived DA release	71
5.4.	Summary of the influence of L-DOPA on extracellular levels of DA	71
6.	New perspectives on the L-DOPA modulation of dopaminergic transmission	72
6.1.	Revisiting the significance of L-DOPA-induced striatal release of DA	72
6.2.	The broader enhancement of DA transmission by L-DOPA in extra-striatal regions	72
6.3.	Significance of striatal and extra-striatal actions of L-DOPA in comparison with other antiparkinson strategies	74
6.4.	Summary of L-DOPA induced DA release throughout the brain	76
7.	Influence of L-DOPA on generation and release of other classes of neurotransmitter	76
7.1.	L-DOPA and its influence on tissue and extracellular levels of 5-HT	76
7.2.	L-DOPA and its influence on tissue and extracellular levels of NA	77
7.3.	L-DOPA and its influence on tissue and extracellular levels of acetylcholine	78
7.4.	L-DOPA and its influence on tissue and extracellular levels of GABA and glutamate	78
8.	Intrinsic actions of L-DOPA other than those modulating transmitter release	79
8.1.	Potential DA-independent mechanisms triggered by L-DOPA	79
8.2.	Endogenous L-DOPA as a putative neurotransmitter	80
8.3.	Actions mediated by metabolites of L-DOPA	80
8.4.	Incorporation of L-DOPA into proteins	80
8.5.	Summary of potential DA-independent, intrinsic actions of L-DOPA	81
9.	Neurochemistry of L-DOPA following chronic administration in relation to onset of dyskinesia	81
9.1.	Alteration of striatal DA transmission in L-DOPA-induced dyskinesia	81
9.2.	Relating the temporal pattern of extracellular DA levels to induction of dyskinesia	81
9.3.	Role of serotonergic mechanisms in L-DOPA-induced dyskinesia and its control	83
9.3.1.	The "presynaptic serotonergic hypothesis": focus on 5-HT <sub>1A</sub> and 5-HT <sub>1B</sub> autoreceptors	83
9.3.2.	Beyond the presynaptic serotonergic hypothesis: a role for post-synaptic receptors	85
9.4.	Role of adrenergic mechanisms in L-DOPA-induced dyskinesia	86
9.5.	L-DOPA and the emergence of psychiatric side-effects	86
10.	Potential neurotoxic impact of L-DOPA on dopaminergic and serotonergic neurons	87
11.	Summary of key points and concluding comments	88
	Conflict of interests	89
	Acknowledgments	89
	References	89

## 1. Introduction: Parkinson's disease and its management by L-DOPA, an overview and aims of the review

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the cardinal motor deficits of bradykinesia, rigidity, postural instability and tremor at rest, together with a suite of other symptoms like anosmia, depressed mood, psychosis, sensory disturbances and pain, disruption of sleep and cognitive dysfunction (Hirao et al., 2015; Olanow et al., 2009). Despite several familial forms of PD linked to specific genetic mutations, most patients suffer from idiopathic PD.

It is important not to ignore a widespread and progressive pattern of anomalies in cortico-subcortical circuits and a broad-based disruption of cerebral plasticity, yet the most striking and common feature of PD is the age-related and gradual degeneration

of nigrostriatal dopaminergic pathways innervating the striatum: loss of these neurons is closely linked to the above-mentioned cluster of motor symptoms leading to the diagnosis of PD (Burke and O'Malley, 2013; Hornykiewicz, 2006; Olanow et al., 2009).

L-DOPA acquired its status as a core antiparkinsonian treatment soon after the biochemical demonstration that levels of the neurotransmitter dopamine (DA) are greatly reduced in the caudate nucleus and putamen of PD patients (see Lees et al., 2015). This decrease is, as remarked above, a consequence of the loss of DA neurons in the substantia nigra pars compacta (SNpc), which project to the basal ganglia (Hornykiewicz, 1973), a group of subcortical structures interlinked with the cortex, thalamus and hippocampus and critically involved in the control of motor behavior – as well as cognition, social behavior, reward and mood (Esposito et al., 2007; Obeso et al., 2008a; Pauli et al., 2016). L-

Download English Version:

<https://daneshyari.com/en/article/5739089>

Download Persian Version:

<https://daneshyari.com/article/5739089>

[Daneshyari.com](https://daneshyari.com)